Astaxanthin side effects are not one list that fits every product and every person. A 2019 review of 87 human studies reported no safety concerns with the natural astaxanthin preparations it examined, including 35 studies using at least 12 mg per day. Those studies differed in dose, duration, preparation, and participants. The review does not establish long-term safety for every formula or every population, and it does not rule out rare reactions or drug interactions. [1] Whether that record matches the ingredient in a finished unit is a specification question for an astaxanthin supplement manufacturer.

Quick answer. Human studies of natural astaxanthin have generally reported good tolerability over the doses and durations examined. They do not establish safety for every dose, product, or population. One published case report raises concern about a possible interaction with warfarin. Evidence is limited for children, pregnancy, breastfeeding, and long-term use. The dose and age limits that apply depend on the ingredient and the destination market.

This is not personal medical advice. Dietary supplements are not intended to diagnose, treat, cure, or prevent disease.

What the Human Studies Actually Watched

The 2019 review is a summary of natural-astaxanthin studies, not a single trial and not a synthetic-astaxanthin file. Approved or recommended amounts in the countries it surveyed ranged from 2 mg to 24 mg. That range is not the dose used in every included study. [1] Twelve milligrams appears among the higher doses in that review. Whether 12 mg may be sold is a separate question of ingredient and market, covered with the regulatory conditions below.

The third row is a review, not another clinical trial. Follow-up in the underlying studies generally lasted weeks rather than years. Most participants were healthy adults. Preparations differed, and some work was commercially funded. Children, pregnancy, breastfeeding, and people with complex illness were not the populations studied.

What Regulators Concluded, and for Whom

A risk assessment, a condition of use for one novel food, and a US marketing rule are three different instruments.

In 2020, EFSA assessed 8 mg per day from food supplements together with a high estimate of astaxanthin from the diet, mainly fish and crustaceans. For adults, that combined exposure stayed below the acceptable daily intake of 0.2 mg per kilogram of body weight and was considered safe under the conditions assessed. Adolescents aged 14 to under 18 reached that intake. Children aged 10 to under 14 exceeded it by 28 percent. Infants aged 4–6 months exceeded it by up to 524 percent. [4]

These percentages describe estimated total exposure relative to the ADI in that scenario. They are not observed rates of illness, and they are not evidence that the supplement caused harm in children. An ADI is a health-based reference for average daily intake over time, not a line at which symptoms are expected to start. [4]

Commission Implementing Regulation (EU) 2023/1581 is a later use condition for one novel food: astaxanthin-rich oleoresin from Haematococcus pluvialis. It is not the same document as the EFSA opinion, and it is not a ceiling for every astaxanthin ingredient in every country. In food supplements, the maximum levels of astaxanthin are 2.3 mg per day for children aged 3 to under 10, 5.7 mg per day for adolescents aged 10 to under 14, and 8 mg per day for the general population older than 14. Labels must state that the supplement should not be consumed if other supplements containing astaxanthin esters are taken the same day. They must also carry the age warning that matches the product, including that it is not for infants and young children under 3. Depending on the age group the product is meant for, the warning also covers children under 10, or children and adolescents under 14. [5] The EFSA finding that adolescents aged 14 to under 18 reached the ADI in the 8 mg plus diet scenario is an exposure result. It is not the age cut in this regulation, which sets 8 mg per day for people older than 14 for this oleoresin.

In the United States, dietary supplements are not generally approved by the FDA before marketing. The firm remains responsible for safety and for the labeling rules that apply. If a product contains a new dietary ingredient that is subject to notification, the firm generally must submit that notification at least 75 days before marketing, unless a statutory exception applies. [6] A serving printed on a US label is not, by itself, the EU condition above.

What the Evidence Says About Reported Side Effects

The available studies do not establish a rate, or one list of common adverse effects specific to astaxanthin. A symptom after a supplement may relate to the active ingredient, another component of the formula, an existing condition, or an event that is unrelated. The evidence has to be read for that ingredient and that product. It should not be used to assign every reported symptom to astaxanthin.

The eight-week trial measured blood pressure and did not find a clinically important difference from placebo. [2] A change in hormones has not been established as an adverse effect in these safety studies. That is not the same as proof that every endocrine effect has been ruled out. People with a hormone-sensitive condition, or people on endocrine treatment, should ask their clinician before adding it. Astaxanthin should not be marketed as a hormone treatment on the back of that gap.

A Case Report Involving Warfarin

One published case report raises a clinically important concern about a possible interaction with warfarin. It does not establish the interaction as a general rule, and it does not estimate how often any interaction occurs.

A 69-year-old woman with a prior ischemic stroke was taking warfarin, aspirin, atenolol, digoxin, omeprazole, and simvastatin. Her INR was 1.4. She then started 4 mg astaxanthin capsules: two capsules the first evening, and the next day two in the morning and two in the evening, which is 16 mg on that second day. Bruising appeared. Her INR rose to 10.38. Warfarin and astaxanthin were stopped, vitamin K was given, and the INR returned to 1.43 as the bruising improved. The authors judged the relationship probable. [7]

The practical step is narrower than a class-wide warning. Someone taking warfarin should ask the prescriber or a pharmacist before starting astaxanthin. An abnormal INR or bleeding symptoms need prompt medical assessment. Evidence for other anticoagulants and antiplatelet medicines is too limited to treat this case as proof that each of those drugs interacts in the same way. People taking them, or heading into a procedure, should still ask before they start, because the record does not clear those situations either.

Liver, Kidneys, and Hormones

In the eight-week trial, the metabolic panel showed no clinically important difference from placebo. [2] In the four-week evaluation of an H. pluvialis extract at 4 mg, 8 mg, and 20 mg as astaxanthin dialcohol, no abnormality was reported in the blood measures. [3] Neither result is a study of chronic liver disease, chronic kidney disease, or long-term organ safety. Someone whose liver or kidney tests are already being followed should ask the clinician who orders them. A formula can also contain minerals or other actives that a renal diet restricts.

Who Should Ask a Clinician First

Adult tolerability data should not be copied onto groups the trials did not enroll.

Children should not be given an adult serving. The EFSA figures above are exposure estimates for an 8 mg supplement plus diet. The EU maximums above apply only to H. pluvialis oleoresin, and they are lower for ages 3 to under 14 than for people older than 14. Infants and young children under 3 are outside that use. [4][5]

Pregnancy and breastfeeding do not have an adequate trial for routine use. Many supplements have not been properly studied in pregnancy, nursing, or children. [8]

People on prescription or nonprescription medicine should ask before they start, using the warfarin report as a reason for that question rather than as a list of interacting drugs. [7] The same applies to people treated for liver, kidney, cardiovascular, immune, endocrine, bleeding, or metabolic disease: the caution is the missing evidence, not a trial that showed harm.

Allergies follow the whole unit. Astaxanthin from microalgae is not shellfish astaxanthin. The capsule can still contain fish oil, krill oil, gelatin, a soy-derived carrier, or another allergen. A vegan or allergen-free claim has to cover the carrier and the shell.

Anyone who has already reacted should stop the product and have the cause assessed. The earlier reaction may have been the carotenoid, another ingredient, a quality problem, or something unrelated.

Skin Color

Carotenodermia is a yellow-to-orange skin color from carotenoid deposited in the outer skin. A review of about 100 cases linked that pattern to high beta-carotene intake, often on thicker skin such as the palms, with the sclera left clear. [9] The review is not a set of astaxanthin supplement cases. It does not show that an astaxanthin product cannot change skin color, especially when the formula also contains beta-carotene or lycopene. It also does not make a change in skin color an expected effect of the adult doses in the trials above.

Natural and Synthetic Are Not the Same Safety File

Natural astaxanthin in human supplements is commonly an extract of Haematococcus pluvialis. Synthetic astaxanthin is a different material, widely used in feed, and the 2019 review said it should not inherit the human record for the natural form. [1] Ester form, isomer pattern, impurities, and legal status can differ. For safety, the data have to match the ingredient on the specification.

If a Reaction Happens

Stop the product. Get medical care when symptoms are serious, include bleeding or an abnormal INR, or do not settle. Keep the bottle, the lot number, and a note of the amount taken and when the symptom started. Tell the brand or the seller. In the United States, a serious illness that may be linked to a dietary supplement can be reported to the FDA. [10]

For supplement brands, the practical question is whether the evidence matches the ingredient and the finished formula being sold. A study of one preparation in healthy adults does not establish the safety of another source, a different formula, or a product meant for a different population. Ingredient identity, the assay, the contaminant controls that fit that process, the other components, and the destination-market rules have to be set against that product and its label.

FAQ

What are the most common astaxanthin side effects? The trials and the 2019 review did not establish one common, ingredient-specific list. A symptom can still come from the carotenoid, another ingredient, or an unrelated illness. [1]

Is astaxanthin dangerous? Natural astaxanthin was generally well tolerated in the healthy adults and the time frames that were studied. That result does not cover every dose, every age, or every medicine. [1][4]

Can astaxanthin damage the liver or the kidneys? The short adult studies that checked blood chemistry did not show a consistent injury signal. [2][3] They did not study chronic liver or kidney disease.

Does astaxanthin affect hormones? A hormone-related adverse effect has not been established in these safety studies. The studies also did not rule every endocrine effect out. [1]

Can astaxanthin interact with warfarin? One case report describes a possible interaction, not a rate. INR rose from 1.4 to 10.38 after a woman on warfarin started 4 mg capsules and took 16 mg the next day, with bruising. The authors called the link probable. Ask the prescriber before starting, and get prompt care for an abnormal INR or bleeding. [7]

Does astaxanthin change skin color? The carotenodermia review is about high beta-carotene intake, not astaxanthin supplements. Other carotenoids in the same formula can still change the judgment. Skin color should not be described as either impossible or routine. [9]

Is 12 mg of astaxanthin too much? Twelve milligrams was used in adult studies that did not flag a safety concern. [1] EFSA’s adult conclusion was a different scenario: 8 mg a day from supplements plus diet. [4] For the EU oleoresin, 8 mg a day is the maximum for people older than 14. [5] Permission depends on the ingredient and the country.

Can children, or someone who is pregnant, take astaxanthin? Adult results should not be copied onto children. For the EU H. pluvialis oleoresin, infants and young children under 3 are excluded, and ages 3 to under 14 have lower maximums than people older than 14. [5] Pregnancy and breastfeeding lack an adequate trial for routine use. [8]

Related

• Lutein Supplements
• Eye Health Supplements
• Beauty Supplements

Technical and Regulatory References

1. Brendler T, Williamson EM. Astaxanthin: how much is too much? A safety review. Phytotherapy Research. 2019;33(12):3090-3111. https://doi.org/10.1002/ptr.6514 · https://pubmed.ncbi.nlm.nih.gov/31788888/
2. Spiller GA, Dewell A. Safety of an astaxanthin-rich Haematococcus pluvialis algal extract: a randomized clinical trial. Journal of Medicinal Food. 2003;6(1):51-56. https://doi.org/10.1089/109662003765184741 · https://pubmed.ncbi.nlm.nih.gov/12804020/
3. Satoh A, Tsuji S, Okada Y, Murakami N, Urami M, Nakagawa K, Ishikura M, Katagiri M, Koga Y, Shirasawa T. Preliminary clinical evaluation of toxicity and efficacy of a new astaxanthin-rich Haematococcus pluvialis extract. Journal of Clinical Biochemistry and Nutrition. 2009;44(3):280-284. https://doi.org/10.3164/jcbn.08-238 · https://pubmed.ncbi.nlm.nih.gov/19430618/
4. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). Safety of astaxanthin for its use as a novel food in food supplements. EFSA Journal. 2020;18(2):5993. https://doi.org/10.2903/j.efsa.2020.5993 · https://pubmed.ncbi.nlm.nih.gov/32874213/
5. European Commission. Commission Implementing Regulation (EU) 2023/1581 of 1 August 2023 amending Implementing Regulation (EU) 2017/2470 as regards the conditions of use of the novel food astaxanthin-rich oleoresin from Haematococcus pluvialis algae. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32023R1581
6. U.S. Food and Drug Administration. New Dietary Ingredients in Dietary Supplements — Background for Industry. https://www.fda.gov/food/new-dietary-ingredient-ndi-notification-process/new-dietary-ingredients-dietary-supplements-background-industry
7. Santiyanon N, Yeephu S. Interaction between warfarin and astaxanthin: a case report. Journal of Cardiology Cases. 2019;19(5):173-175. https://doi.org/10.1016/j.jccase.2019.01.002 · https://pubmed.ncbi.nlm.nih.gov/31073352/
8. National Center for Complementary and Integrative Health. Using Dietary Supplements Wisely. National Institutes of Health. https://www.nccih.nih.gov/health/using-dietary-supplements-wisely
9. Kapsetaki ME. Diet-induced carotenodermia: a literature review. International Journal of Dermatology. 2023. https://pubmed.ncbi.nlm.nih.gov/37916485/
10. U.S. Food and Drug Administration. How to Report a Problem with Dietary Supplements. https://www.fda.gov/food/dietary-supplements/how-report-problem-dietary-supplements

Disclaimer

Educational reference only. Not personal medical, legal, or regulatory advice, and not intended to diagnose, treat, cure, or prevent any disease. Study conditions and a regulatory exposure scenario are not a recommended intake. A technically feasible formula still has to meet the ingredient authorization, claims, and population rules of the destination market. KS Nutripharma manufactures to an agreed specification and does not approve claims.

Written by the KS Nutripharma formulation team | Evidence and regulatory references checked for editorial accuracy, not as a clinical medical review | Updated October 12, 2026

About KS Nutripharma: KS Nutripharma